IFNA2 and metastatic neoplasm: For example, IFN-α2b combined with sorafenib achieved an overall response rate of 33% in patients with metastatic disease [4]; IFN-α2b combined with temsirolimus was not as effective as temsirolimus alone [5]; and IFN-α combined with bevacizumab significantly increased progression-free survival and objective responses [6].